| 生物活性 |
Basimglurant (RG7090; RO4917523) is a selective, orally active, blood-brain barrier-penetrant negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5) with a Ki of 1.4 nM (against [³H]-ABP688 (MS-T13256)) and 35.6 nM (against [³H]-MPEP (MS-X10413)); it inhibits mGlu5-mediated signaling pathways and receptor constitutive activity, modulates accumbal dopamine levels, exerts anxiolytic, antidepressant-like, analgesic, and wake-promoting effects, and alters delta wave power during non-rapid eye movement sleep, and can be used for research on depression, fragile X syndrome, anxiety disorders, and other conditions. |
体内研究 (In Vivo) |
Basimglurant (1-3 mg/kg;腹腔注射,每日给药,连续 21 天) 在慢性温和应激诱导快感缺失的大鼠中表现出显著的类抗抑郁活性。 Basimglurant (10-30 mg/kg;口服;24 小时内给药 3 次) 可在大鼠强迫游泳实验中产生类抗抑郁作用。 Basimglurant (1-30 mg/kg;口服;单次给药) 可在大鼠中诱导与典型抗抑郁药高度相似的脑活动模式。 Basimglurant (0.03-0.3 mg/kg;口服;单次给药) 在大鼠 Vogel 冲突试验中表现出类抗焦虑活性。 Basimglurant (0.01-1 mg/kg;口服;单次给药) 在小鼠应激诱导的体温过高试验中发挥抗焦虑作用。 Basimglurant (0.3-1 mg/kg;口服;单次给药) 在大鼠条件性情绪反应试验中表现出类抗焦虑活性。 Basimglurant (0.1-1 mg/kg;口服;单次给药) 在大鼠恐惧增强惊跳实验中产生类抗焦虑作用。 Basimglurant (10 mg/kg;口服;单次给药) 在小鼠福尔马林诱导疼痛模型的晚期阶段表现出镇痛活性。 Basimglurant (0.1-10 mg/kg;皮下注射;单次给药) 可剂量依赖性地抑制坐骨神经结扎大鼠的冷异常痛觉。 Basimglurant (0.03-0.3 mg/kg;静脉注射;单次给药) 可剂量依赖性地提高麻醉大鼠的排尿阈值容量。 Basimglurant (0.01-0.03 mg/kg;静脉注射;单次给药) 可强效降低麻醉大鼠的膀胱收缩频率。 basimglurant (0.03-0.3 mg/kg;口服;每日一次;连续 5 天) 可在挪威大鼠的活动暗期产生剂量依赖性的促觉醒作用,减少快速眼动 (REM) 睡眠和非快速眼动 (non-REM) 睡眠,延长睡眠潜伏期,并增强非快速眼动睡眠的 δ 波功率。
| Animal Model: |
Wistar rats (male, 350 g, chronic mild stress-induced anhedonia model with unilateral ventral tegmental area electrode implantation) |
| Dosage: |
1 mg/kg; 3 mg/kg |
| Administration: |
i.p.; daily; 21 days |
| Result: |
Reduced the anhedonia index by -72% (day 35), -53% (day 39), and -64% (day 42) compared to vehicle-treated stressed rats at 3 mg/kg, normalizing values to pre-stress baseline levels. Reduced the anhedonia index significantly with consistent effects across the treatment period at 1 mg/kg. Had no significant effect on anhedonia index in unstressed rats. |
| Animal Model: |
Wistar rats (male, 350 g, chronic mild stress-induced anhedonia model with unilateral ventral tegmental area electrode implantation) |
| Dosage: |
1 mg/kg; 3 mg/kg |
| Administration: |
i.p.; daily; 21 days |
| Result: |
Reduced the anhedonia index by -72% (day 35), -53% (day 39), and -64% (day 42) compared to vehicle-treated stressed rats at 3 mg/kg, normalizing values to pre-stress baseline levels. Reduced the anhedonia index significantly with consistent effects across the treatment period at 1 mg/kg. Had no significant effect on anhedonia index in unstressed rats. |
| Animal Model: |
Sprague Dawley rats (male, 190-210 g, Vogel conflict drinking test model) |
| Dosage: |
0.03 mg/kg; 0.1 mg/kg; 0.3 mg/kg |
| Administration: |
p.o.; single dose; 1 hour pre-test |
| Result: |
Increased punished drinking time by +165% at 0.03 mg/kg, with further increases at higher doses, reaching significance at all tested doses compared to vehicle. |
| Animal Model: |
Fischer F344 rats (male, ~250 g, fMRI-based brain activity profiling model) |
| Dosage: |
1 mg/kg; 10 mg/kg; 30 mg/kg |
| Administration: |
p.o.; single dose; 1 hour pre-fMRI imaging |
| Result: |
Increased perfusion in the dorsal striatum and decreased perfusion in the medial prefrontal cortex, dorsal hippocampus, thalamus, hypothalamus, septum, nucleus accumbens, ventral pallidum, and entorhinal piriform cortex at 1 mg/kg. Amplified the perfusion changes observed at 1 mg/kg at 10 mg/kg. Showed a pattern match coefficient (PMC) of >0.71 compared to prototypical antidepressants including duloxetine, reboxetine, imipramine, bupropion, and electroconvulsive treatment (ECT) at 1 and 10 mg/kg. Surpassed the root mean square (RMS) response strength of ECT and standard antidepressants at 30 mg/kg at 1 and 10 mg/kg. |
| Animal Model: |
Sprague Dawley rats (male, 190-210 g, Vogel conflict drinking test model) |
| Dosage: |
0.03 mg/kg; 0.1 mg/kg; 0.3 mg/kg |
| Administration: |
p.o.; single dose; 1 hour pre-test |
| Result: |
Increased punished drinking time by +165% at 0.03 mg/kg, with further increases at higher doses, reaching significance at all tested doses compared to vehicle. |
| Animal Model: |
NMRI mice (male, ~22 g, stress-induced hyperthermia model) |
| Dosage: |
1 mg/kg; 10 mg/kg; 30 mg/kg |
| Administration: |
p.o.; single dose; 1 hour pre-test |
| Result: |
Reduced stress-induced hyperthermia by -48% at 0.01 mg/kg, -73% at 0.1 mg/kg, and -145% at 1 mg/kg compared to vehicle, with all doses producing significant effects. |
| Animal Model: |
Sprague Dawley rats (male, 350 g, conditioned emotional response model) |
| Dosage: |
0.03 mg/kg; 0.1 mg/kg |
| Administration: |
p.o.; single dose; 1 hour pre-test |
| Result: |
Increased the suppression ratio by +567% at 0.3 mg/kg and +583% at 1 mg/kg compared to vehicle, indicating reduced fear response. |
| Animal Model: |
Sprague Dawley rats (male, 225-287 g, fear-potentiated startle model) |
| Dosage: |
0.03 mg/kg; 0.1 mg/kg |
| Administration: |
p.o.; single dose; 1 hour pre-test |
| Result: |
Reduced fear-potentiated startle amplitude by -53% at 0.1 mg/kg and -94% at 1 mg/kg compared to vehicle, with significant effects at both doses. |
| Animal Model: |
NMRI mice (male, 24-30 g, formalin-induced paw licking model, late phase) |
| Dosage: |
1 mg/kg; 10 mg/kg |
| Administration: |
p.o.; single dose; 40 minutes pre-formalin injection |
| Result: |
Reduced paw licking time by -91% (non-significant) at 1 mg/kg and -95% (significant) at 10 mg/kg compared to vehicle in the late phase of formalin-induced pain. Had no significant effect in the early phase at any tested dose. |
| Animal Model: |
Sprague Dawley rats (female, 100-250 g, Bennett model of cold allodynia with sciatic nerve constriction injury) |
| Dosage: |
0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 10 mg/kg |
| Administration: |
s.c.; single dose; 60 minutes pre-test |
| Result: |
Increased the inhibition rate of cold allodynia by 28% at 0.1 mg/kg, 37% at 0.3 mg/kg, 50% at 1 mg/kg, 39% at 3 mg/kg, and 58% at 10 mg/kg compared to vehicle. Produced significant effects at all doses, with maximal efficacy comparable to morphine (64% inhibition rate) and duloxetine (56% inhibition rate). |
| Animal Model: |
Sprague Dawley rats (female, 200-250 g, volume-induced micturition reflex model with cannulated bladders, anesthetized) |
| Dosage: |
0.03 mg/kg; 0.3 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Increased the micturition threshold volume by +27% at 0.03 mg/kg and +166.9% at 0.3 mg/kg compared to baseline, with significant effects at both doses. |
| Animal Model: |
Sprague Dawley rats (female, 200-250 g, isovolumetric bladder contraction model with cannulated bladders, anesthetized) |
| Dosage: |
0.01 mg/kg; 0.03 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Reduced bladder contraction frequency by -88.5% at 0.01 mg/kg and -79.9% at 0.03 mg/kg compared to vehicle, with maximal effects comparable at both doses. |
|